US-based biotechnology firm MabVax Therapeutics has started dosing patients in a Phase I clinical trial of MVT-1075 to treat patients with CA19-9 positive malignancies such as pancreatic, colon and lung cancers.

Designed to combine radiation therapy and tumour specific targeting, MVT-1075 is a radioimmunotherapy (RIT) candidate comprising small doses of MVT-5873 antibody coupled with radioisotope for targeting and destroying pancreatic cancer cells. 

The open-label, multi-centre, dose-escalation Phase I trial will investigate the safety and efficacy of MVT-1075 in approximately 22 patients with recurring disease at Honour Health in Scottsdale, Arizona and Memorial Sloan Kettering Cancer Centre in New York City. 

The trial’s primary objective is the determination of maximum tolerated dose and safety profile, while the secondary endpoints include tumour response rate and duration, dosimetry and pharmacokinetics. 

"This is the third HuMab-5B1based clinical trial that the company has initiated in the last 16 months."

MabVax Therapeutics president and CEO David Hansen said: "This is the third HuMab-5B1based clinical trial that the company has initiated in the last 16 months.

“We believe that the development of this product candidate expands our pipeline to include a more potent therapy combining the clinically demonstrated tumour targeting characteristics of our fully human HuMab-5B1 antibody and commercially validated 177Lutetium, to deliver a dose of radiation to the targeted cancer cells.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With interim data expected by the end of this year, the Phase I trial of MVT-1075 RIT is said to be supported by the preclinical data and results obtained from a Phase Ia trial.

While the product suppressed tumour growth in preclinical models with pancreatic cancer, the Phase Ia trial validated its safety and target specificity.